scholarly journals Role of Direct Oral Anticoagulation Agents as Thromboprophylaxis in Antiphospholipid Syndrome

Cureus ◽  
2021 ◽  
Author(s):  
Shreya Arora ◽  
Shaalina Nair ◽  
Rishab Prabhu ◽  
Chaithanya Avanthika ◽  
Sharan Jhaveri ◽  
...  
Keyword(s):  
Antiphospholipid Syndrome ◽  
Oral Anticoagulation ◽  
Anticoagulation Agents

scholarly journals Pediatric Antiphospholipid Syndrome: from Pathogenesis to Clinical Management

2021 ◽  
Vol 23 (2) ◽  
Author(s):  
Silvia Rosina ◽  
Cecilia Beatrice Chighizola ◽  
Angelo Ravelli ◽  
Rolando Cimaz
Keyword(s):  
Antiphospholipid Syndrome ◽  
Fluid Phase ◽  
Multiple Organ ◽  
Clinical Settings ◽  
Glycoprotein I ◽  
Long Term Follow Up ◽  
Pediatric Populations ◽  
Cellular Components

Abstract Purpose of Review Elucidating the pathogenic mechanisms mediated by antiphospholipid antibodies (aPL) might exert important clinical implications in pediatric antiphospholipid syndrome (APS). Recent Findings aPL are traditionally regarded as the main pathogenic players in APS, inducing thrombosis via the interaction with fluid-phase and cellular components of coagulation. Recent APS research has focused on the role of β2 glycoprotein I, which bridges innate immunity and coagulation. In pediatric populations, aPL should be screened in appropriate clinical settings, such as thrombosis, multiple-organ dysfunction, or concomitant systemic autoimmune diseases. Children positive for aPL tests often present non-thrombotic non-criteria manifestations or asymptomatic aPL positivity. In utero aPL exposure has been suggested to result in developmental disabilities, warranting long-term follow-up. Summary The knowledge of the multifaceted nature of pediatric APS should be implemented to reduce the risk of underdiagnosing/undertreating this condition. Hopefully, recent pathogenic insights will open new windows of opportunity in the management of pediatric APS.

Cardiac involvement in antiphospholipid syndrome: The diagnostic role of noninvasive cardiac imaging

2016 ◽  
Vol 45 (5) ◽  
pp. 611-616 ◽  
Author(s):  
Sophie I. Mavrogeni ◽  
Petros P. Sfikakis ◽  
George D. Kitas ◽  
Genovefa Kolovou ◽  
Maria G. Tektonidou
Keyword(s):  
Antiphospholipid Syndrome ◽  
Cardiac Imaging ◽  
Cardiac Involvement ◽  
Noninvasive Cardiac Imaging ◽  
Diagnostic Role

The Role of Antiphospholipid Syndrome in Critical Illness

2000 ◽  
pp. 419-425 ◽  
Author(s):  
F. M. K. Williams ◽  
G. R. V. Hughes ◽  
R. M. Leach
Keyword(s):  
Critical Illness ◽  
Antiphospholipid Syndrome

scholarly journals Pathogenic and Therapeutic Role of Vitamin D in Antiphospholipid Syndrome Patients

10.5772/65071 ◽  
2017 ◽  
Author(s):  
Svetlana Jelic ◽  
Dejan Nikolic ◽  
Dragomir Marisavljević ◽  
Ljudmila Stojanovich
Keyword(s):  
Vitamin D ◽  
Antiphospholipid Syndrome ◽  
Therapeutic Role

scholarly journals Population-Based Screening for Atrial Fibrillation

2020 ◽  
Vol 127 (1) ◽  
pp. 143-154 ◽  
Author(s):  
Shaan Khurshid ◽  
Jeffrey S. Healey ◽  
William F. McIntyre ◽  
Steven A. Lubitz
Keyword(s):  
Atrial Fibrillation ◽  
Current Literature ◽  
Oral Anticoagulation ◽  
Electronic Devices ◽  
Population Based ◽  
Consensus Guidelines ◽  
Consumer Electronic ◽  
Receive Treatment

Atrial fibrillation (AF) is a common and morbid arrhythmia. Stroke is a major hazard of AF and may be preventable with oral anticoagulation. Yet since AF is often asymptomatic, many individuals with AF may be unaware and do not receive treatment that could prevent a stroke. Screening for AF has gained substantial attention in recent years as several studies have demonstrated that screening is feasible. Advances in technology have enabled a variety of approaches to facilitate screening for AF using both medical-prescribed devices as well as consumer electronic devices capable of detecting AF. Yet controversy about the utility of AF screening remains owing to concerns about potential harms resulting from screening in the absence of randomized data demonstrating effectiveness of screening on outcomes such as stroke and bleeding. In this review, we summarize current literature, present technology, population-based screening considerations, and consensus guidelines addressing the role of AF screening in practice.

P6163Promotion of coronary plaque progression associated with different anticoagulation agents - a longitudinal CTA analysis

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
C Beyer ◽  
M Wildauer ◽  
G Feuchtner ◽  
G Friedrich ◽  
F Hintringer ◽  
...  
Keyword(s):  
Vitamin K ◽  
Oral Anticoagulation ◽  
Vitamin K Antagonist ◽  
Controlled Study ◽  
Time Interval ◽  
Plaque Volume ◽  
Equal Distribution ◽  
Anticoagulation Agents ◽  
Progression Of Atherosclerosis

Abstract Objective Possible antithrombotic effect of anticoagulants in coronary artery disease have been proposed but mechanism are poorly understood. Experimental and clinical data indicate a key role of coagulation factors in the progression of atherosclerosis. We sought to evaluate the effect of different oral anticoagulation agents on the progression of atherosclerosis. Methods This retrospective matched case controlled study included patients with atrial fibrillation (AF) who underwent repeated CT angiography for ablation planning. Patients with known structural cardiac pathologies or significant comorbidities were excluded. Patients were stratified according to their anticoagulation into 3 groups: vitamin K antagonist (VKA), direct oral anticoagulation (DOAC) and control (CR; aspirin or no therapy) with equal distribution of age and cardiovascular risk factors. Baseline and follow-up CT exams for repeated AF ablations were evaluated for the CAD profile and (semi)automated quantitative plaque analysis. Results One-hundred sixty-one patients were included (mean CT time interval: 31 months). The three cohorts did not differ in patient characteristics or CT findings at baseline. Absolute plaque volume progression was significantly higher in patients using VKA (66.5±136.7 mm3) compared to both CR (27.2±73.6 mm3) and DOAC (−7.1±42.1 mm3, p<0.001), translating into an annual change of 23.2±47.0 mm3 for VKA, 12.3±4.3 mm3 for CR and −4.6±22.9 mm3 for DOAC (p=0.003). The number of affected segments (SIS) increased by 1.2±1.3 compared to 0.6±1.3 in the control group and 0.2±0.7 in the DOAC group (p<0.0001). Baseline CTA findings Control (n=61) DOAC (n=50) VKA (n=50) p Vessel Volume (mm3) 26.9±42.9 23.1±43.3 27.9±40.7 0.85 Lumen Volume (mm3) 15.7±24.8 13.3±25.1 16.6±27.0 0.82 Coronary Calcium Score (AU) 63.4±187.2 42.0±114.6 53.8±118.6 0.75 Segment Involvement Score 1.8±2.1 1.8±2.3 1.9±2.2 0.96 Stenosis Average Area (%) 19.0±21.7 0.5±0.7 0.5±0.7 0.71 Maximal Plaque Thickness (mm3) 0.5±0.7 0.5±0.7 0.5±0.7 0.69 Total Plaque Volume (mm3) 33.6±60.0 30.0±55.6 34.2±48.0 0.92 AU, Agatston units; DOAC, direct oral anticoagulation; SIS, segment involvement score; VKA, vitamin K antagonist. Changes between baseline and follow-up Conclusion In serial coronary CTs, patients using vitamin K antagonists showed the highest plaque volume progression while patients using a direct oral anticoagulant showed a regression of total plaque volume. Therefore, direct anticoagulation may have a beneficial effect on atherosclerosis.

scholarly journals PERI-PROCEDURAL USE OF NOVEL ORAL ANTICOAGULATION AGENTS DURING CARDIAC DEVICE IMPLANTATION: ARE THEY SAFE?

2017 ◽  
Vol 69 (11) ◽  
pp. 309
Author(s):  
Valay Parikh ◽  
Madhav Lavu ◽  
Venkat Lakshmi Kishan Vuddanda ◽  
Mohammad Jazayeri ◽  
Vidhya Reddy ◽  
...  
Keyword(s):  
Oral Anticoagulation ◽  
Cardiac Device ◽  
Device Implantation ◽  
Anticoagulation Agents
Sign in / Sign up

Export Citation Format

Share Document